Zelira Therapeutics Limited

Equities

ZLD

AU000000ZLD1

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 01:44:48 2024-04-26 am EDT			5-day change	1st Jan Change
0.705 ^AUD	-0.70%		-2.08%	-21.67%

Apr. 15	Zelira Therapeutics Receives AU$919,000 Funding Under Australian Government’s R&D Tax Incentive Scheme	MT
Feb. 22	Zelira Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

Zelda Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2018

February 22, 2019 at 03:36 am EST

Zelda Therapeutics Limited announced earnings results for the half year ended December 31, 2018. For the half year, the company announced net loss was AUD 2.063 million compared to AUD 496,648 a year ago. Basic loss per share was AUD 0.0027 compared to AUD 0.0007 a year ago.

Latest news about Zelira Therapeutics Limited

Zelira Therapeutics Receives AU$919,000 Funding Under Australian Government’s R&D Tax Incentive Scheme	Apr. 14	MT
Zelira Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 22	CI
Zelira Therapeutics Secures Grant Funding for Cannabinoid Product	Jan. 07	MT
Transcript : Zelira Therapeutics Limited - Shareholder/Analyst Call	Nov. 14
Zelira Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Zelira Therapeutics Limited Announces Board Changes	23-05-31	CI
Transcript : Zelira Therapeutics Limited - Special Call	23-05-30
Zelira Therapeutics Bags Nearly AU$5 Million More Investment for HOPE SPV; Shares Rise 4%	23-05-21	MT
Zelira Therapeutics Limited announced that it expects to receive $22 million in funding	23-05-21	CI
Zelira Therapeutics Raises AU$1.8 Million Via Placement	23-03-15	MT
Zelira Therapeutics Halts Securities Trading Pending Capital Raising Announcement	23-03-13	MT
Zelira Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-27	CI
Transcript : Zelira Therapeutics Limited - Special Call	23-02-21
Zelira Therapeutics Limited Promotes Greg Blake from VP - Global Head of Commercial and Partnering to Executive Director	23-02-19	CI
Zelira Therapeutics Secures Nearly $9 Million Funding for US Clinical Trials of HOPE	23-02-15	MT
Zelira Therapeutics Secures R&D Tax Rebate	23-01-30	MT
Zelira Therapeutics Completes Drug Trial Patient Enrolment	22-11-21	MT
Transcript : Zelira Therapeutics Limited - Shareholder/Analyst Call	22-11-16
Zelira Therapeutics Launches ZYRAYDI™ B2b Technology to Create Pharma-Grade Cannabis Capsules & Tablets for Global Markets	22-09-20	CI
Zelira Therapeutics Enrolls Two-Thirds of Patients for Diabetic Nerve Pain Medication	22-09-14	MT
Zelira Therapeutics Limited Completes Two-Thirds of Enrolment for Diabetic Nerve Pain Drug Trial	22-09-14	CI
Zelira Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-31	CI
Zelira Therapeutics Limited Auditor Raises 'Going Concern' Doubt	22-08-30	CI
Zelira's Zenivol™, the First Clinically Validated Cannabinoid Medication for Insomnia, Achieves Regulatory Approval in Germany	22-07-21	CI
Zelira Therapeutics Secures German Regulatory Approval for Insomnia Drug; Shares Rally 13%	22-07-13	MT

Chart Zelira Therapeutics Limited

Duration

Period

More charts

Company Profile

Zelira Therapeutics Limited is an Australia-based biopharmaceutical company. The Company is engaged in the research, development and commercialization of clinically validated cannabinoid-based medicines. It owns a portfolio of products and a pipeline of candidates undergoing clinical development positioned to enter global markets. It is focused on developing and clinically validating branded cannabinoid-based medicines in its prescription [Rx] business for the treatment of a variety of medical conditions, including insomnia, autism and chronic non-cancer pain, as well as offering over the counter [OTC] products. It has two medications: HOPE and ZENIVOL. ZENIVOL is a cannabinoid-based medicine for the treatment of chronic insomnia. The Company in partnership with SprinJeneCBD, introduced a full line of oral care products, including SprinJeneCBD toothpaste product, which is a hemp-derived, oral care products containing cannabinoids, blackseed oil and zinc utilizing patented technology.

Sector

Biotechnology & Medical Research

Calendar

2024-08-28 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ZELIRA THERAPEUTICS LIMITED	-21.67%	5.24M
VERTEX PHARMACEUTICALS INCORPORATED	-2.25%	103B
REGENERON PHARMACEUTICALS, INC.	+0.64%	95.71B
ARGENX SE	+1.69%	22.02B
BIONTECH SE	-17.09%	20.9B
GENMAB A/S	-9.30%	17.85B
WUXI APPTEC CO., LTD.	-41.01%	16.21B
BEIGENE, LTD.	-14.70%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+2.99%	13.86B
SAREPTA THERAPEUTICS, INC.	+34.37%	12.04B

Bio Therapeutic Drugs